Benzalkonium chloride in glaucoma medications

Ocular Surface

Volumn 9, Issue 3, 2011, Pages 159-162

  Noecker, Robert ^a   Miller, Kimberly V ^b  

^a Ophthalmic Consultants of Connecticut   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Benzalkonium chloride; Eye drops; Glaucoma; Ocular toxicity; Preservatives; Topical ocular formulations

Indexed keywords

ANTIGLAUCOMA AGENT; BENZALKONIUM CHLORIDE; BETAXOLOL; EYE DROPS; LATANOPROST; MUCIN; RYSMON TG; TAFLUPROST; TIMOLOL; TIMOLOL MALEATE; TRAVOPROST; UNCLASSIFIED DRUG;

CELL DAMAGE; CONJUNCTIVA EPITHELIUM; CORNEA CELL; CORNEA INJURY; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EPITHELIUM CELL; EYE TOXICITY; GLAUCOMA; HUMAN; NONHUMAN; REVIEW; TOPICAL TREATMENT; WOUND HEALING;

EID: 80051714787     PISSN: 15420124     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1542-0124(11)70025-8     Document Type: Review

References (46)

1. A yaki M, Noda Y, Yaguchi S, et al. [Cytotoxicity of antiglaucoma ophthalmic solutions for human corneal endothelial cells]. Nippon Ganka Gakkai Zasshi 2009;113:576-82. Japanese
2. Tripathi BJ, Tripathi RC . Cytotoxic effects of benzalkonium chloride and chlorobutanol on human corneal epithelial cells in vitro. Lens Eye Toxic Res 1989;6:395-403 (Pubitemid 19234248)
3. Takahashi N. Quantitative cytotoxicity of preservatives evaluated in cell culture with Chang's human conjunctival cells--effect of temperature on cytotoxicity. Jpn J Ophthalmol 1982;26:234-238 (Pubitemid 12080619)
4. Tripathi BJ, Tripathi RC, Kolli SP. Cytotoxicity of ophthalmic preservatives on human corneal epithelium. Lens Eye Toxic Res 1992;9:361-375 (Pubitemid 23111708)
5. De Saint Jean M, Brignole F, Bringuier AF, et al. Effects of benzalkonium chloride on growth and survival of Chang conjunctival cells. Invest Ophthalmol Vis Sci 1999;40:619-630 (Pubitemid 29109440)
6. Debbasch C, Brignole F, Pisella PJ, et al. Quaternary ammoniums and other preservatives' contribution in oxidative stress and apoptosis on Chang conjunctival cells. Invest Ophthalmol Vis Sci 2001;42:642-652 (Pubitemid 32206903)
7. A yaki M, Yaguchi S, Iwasawa A, Koide R. Cytotoxicity of ophthalmic solutions with and without preservatives to human corneal endothelial cells, epithelial cells and conjunctival epithelial cells. Clin Experiment Ophthalmol 2008;36:553-559
8. C hung SH, Lee SK, Cristol SM, et al. Impact of short-term exposure of commercial eyedrops preserved with benzalkonium chloride on precorneal mucin. Mol Vis 2006;12:415-21
9. E pstein SP, Chen D, Asbell PA. Evaluation of biomarkers of inflammation in response to benzalkonium chloride on corneal and conjunctival epithelial cells. J Ocul Pharmacol Ther 2009;25:415-
10. Kawase K, Lin W, Aoyama Y, et al. Effects of timolol-related ophthalmic solutions on cultured human conjunctival cells. Jpn J Ophthalmol 2010;54:615-621
11. A yaki M, Iwasawa A, Yaguchi S, Koide R. Preserved and unpreserved 12 anti-allergic ophthalmic solutions and ocular surface toxicity: in vitro assessment in four cultured corneal and conjunctival epithelial cell lines. Biocontrol Sci 2010;15:143-148
12. Y ee RW, Norcom EG, Zhao XC. Comparison of the relative toxicity of travoprost 0.004% without benzalkonium chloride and latanoprost 0.005% in an immortalized human cornea epithelial cell culture system. Adv Ther 2006;23:511-519
13. A mmar DA, Noecker RJ, Kahook MY. Effects of benzalkonium chloridepreserved, polyquad-preserved, and sofZia-preserved topical glaucoma medications on human ocular epithelial cells. Adv Ther 2010;27:837-845
14. E pstein SP, Ahdoot M, Marcus E, Asbell PA. Comparative toxicity of preservatives on immortalized corneal and conjunctival epithelial cells. J Ocul Pharmacol Ther 2009;25:113-119
15. Ingram PR, Pitt AR, Wilson CG, et al. A comparison of the effects of ocular preservatives on mammalian and microbial ATP and glutathione levels. Free Radic Res 2004;38:739-750 (Pubitemid 38812092)
16. A dams J, Wilcox MJ, Trousdale MD, et al. Morphologic and physiologic effects of artificial tear formulations on corneal epithelial derived cells. Cornea 1992;11:234-41
17. Wilson WS, Duncan AJ, Jay JL. Effect of benzalkonium chloride on the stabilityof the precorneal tear film in rabbit and man. Br J Ophthalmol 1975;59:667-669
18. Green K, Hull DS, Vaughn ED, et al. Rabbit endothelial response to ophthalmic preservatives. Arch Ophthalmol 1977;95:2218-2221 (Pubitemid 8261065)
19. C ollin HB, Grabsch BE. The effect of ophthalmic preservatives on the healing rate of the rabbit corneal epithelium after keratectomy. Am J Optom Physiol Opt 1982;59:215-222
20. C ollin HB. Ultrastructural changes to corneal stromal cells due to ophthalmic preservatives. Acta Ophthalmol (Copenh) 1986;64:72-78
21. C ollin HB, Carroll N. Ultrastructural changes to the corneal endothelium due to benzalkonium chloride. Acta Ophthalmol (Copenh) 1986;64:226-231
22. L opez Bernal D, Ubels JL. Quantitative evaluation of the corneal epithelial barrier: effect of artificial tears and preservatives. Curr Eye Res 1991;10:645-656
23. Ichijima H, Petroll WM, Jester JV, Cavanagh HD. Confocal microscopic studies of living rabbit cornea treated with benzalkonium chloride. Cornea 1992;11:221-225Erratum in Cornea 1992;11:368
24. L abbe A, Pauly A, Liang H, et al. Comparison of toxicological profiles of benzalkonium chloride and polyquaternium-1: an experimental study. J Ocul Pharmacol Ther 2006;22:267-78
25. U ematsu M, Kumagami T, Kusano M, et al. Acute corneal epithelial change after instillation of benzalkonium chloride evaluated using a newly developed in vivo corneal transepithelial electric resistance measurement method. Ophthalmic Res 2007;39:308-14
26. Mietz H, Niesen U, Krieglstein GK. The effect of preservatives and antiglaucomatous medication on the histopathology of the conjunctiva. Graefes Arch Clin Exp Ophthalmol 1994;232:561-565 (Pubitemid 24249226)
27. Becquet F, Goldschild M, Moldovan MS, et al. Histopathological effects of topical ophthalmic preservatives on rat corneoconjunctival surface. Curr Eye Res 1998;17:419-425 (Pubitemid 28178417)
28. Baudouin C, Pisella PJ, Fillacier K, et al. Ocular surface inflammatory changes induced by topical antiglaucoma drugs: human and animal studies. Ophthalmology 1999;106:556-563 (Pubitemid 30191592)
29. Pisella PJ, Fillacier K, Elena PP, et al. Comparison of the effects of preserved and unpreserved formulations of timolol on the ocular surface of albino rabbits. Ophthalmic Res 2000;32:3-8 (Pubitemid 30093503)
30. Noecker RJ, Herrygers LA, Anwaruddin R. Corneal and conjunctival changes caused by commonly used glaucoma medications. Cornea 2004;23:490-496 (Pubitemid 38857008)
31. L iang H, Baudouin C, Faure MO, et al. Comparison of the ocular tolerability of a latanoprost cationic emulsion versus conventional formulations of prostaglandins: an in vivo toxicity assay. Mol Vis 2009;15:1690-9
32. Whitson JT, Cavanagh HD, Lakshman N, Petroll WM. Assessment of corneal epithelial integrity after acute exposure to ocular hypotensive agents preserved with and without benzalkonium chloride. Adv Ther 2006;23:663-671 (Pubitemid 44955845)
33. Kahook MY, Noecker RJ. Comparison of corneal and conjunctival changes after dosing of travoprost preserved with sofZia, latanoprost with 0.02% benzalkonium chloride, and preservative-free artificial tears. Cornea 2008;27:339-343 (Pubitemid 351440870)
34. Kahook MY, Noecker R. Quantitative analysis of conjunctival goblet cells after chronic application of topical drops. Adv Ther 2008;25:743-751
35. Nagai N, Murao T, Okamoto N, Ito Y. Comparison of corneal wound healing rates after instillation of commercially available latanoprost and travoprost in rat debrided corneal epithelium. J Oleo Sci 2010;59:135-141
36. Dong JQ, Babusis DM, Welty DF, et al. Effects of the preservative purite on the bioavailability of brimonidine in the aqueous humor of rabbits. J Ocul Pharmacol Ther 2004;20:285-292 (Pubitemid 39108893)
37. McCarey B, Edelhauser H. In vivo corneal epithelial permeability following treatment with prostaglandin analogs [correction of analoges] with or without benzalkonium chloride. J Ocul Pharmacol Ther 2007;23:445-451 (Pubitemid 350202478)
38. L emp MA, Zimmerman LE . Toxic endothelial degeneration in ocular surface disease treated with topical medications containing benzalkonium chloride. Am J Ophthalmol 1988;105:670-673
39. Gobbels M, Spitznas M. Influence of artificial tears on corneal epithelium in dry-eye syndrome. Graefes Arch Clin Exp Ophthalmol 1989;227:139-141 (Pubitemid 19066679)
40. Gobbels M, Spitznas M. Effects of artificial tears on corneal epithelial permeability in dry eyes. Graefes Arch Clin Exp Ophthalmol 1991;229:345-349
41. C venkel B, Ihan A. Ocular surface changes induced by topical antiglaucoma monotherapy. Ophthalmologica 2002;216:175-179
42. Ishibashi T, Yokoi N, Kinoshita S. Comparison of the short-term effects on thehuman corneal surface of topical timolol maleate with and without benzalkonium chloride. J Glaucoma 2003;12:486-490 (Pubitemid 37494177)
43. Dogan AS, Orhan M, Soylemezoǧlu F, et al. Effects of topical antiglaucoma drugs on apoptosis rates of conjunctival epithelial cells in glaucoma patients. Clin Experiment Ophthalmol 2004;32:62-66 (Pubitemid 38344286)
44. Y amazaki S, Nanno M, Kimura T, et al. Effects of switching to SofZiapreserved travoprost in patients who presented with superficial punctate keratopathy while under treatment with latanoprost. Jpn J Ophthalmol 2010;54:7-14
45. U usitalo H, Chen E, Pfeiffer N, et al. Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication. Acta Ophthalmol 2010;88:329-36
46. R enieri G, Fuhrer K, Scheithe K, et al. Efficacy and tolerability of preservative- free eye drops containing a fixed combination of dorzolamide and timolol in glaucoma patients. J Ocul Pharmacol Ther 2010;26:597-603